Cambridge duo in £1m AI drug discovery project
Cambridge duo Optibrium and Intellegens along with Medicines Discovery Catapult in Cheshire have secured a grant from Innovate UK to fund a £1 million project investigating Artificial Intelligence support for drug discovery.
The programme will see Optibrium, which creates software to improve the efficiency and productivity of drug discovery, and Intellegens, a spin-out from the University of Cambridge focused on a specific form of AI called ‘deep learning’, work with Medicines Discovery Catapult over the next two years.
The aim is to harness the power of AI to learn from complex data and guide scientists in the design and testing of potential new drugs.
Drug discovery generates a huge quantity of complex biological, chemical, clinical and safety information that needs to be collected, analysed and presented in a way that it can be best used to make evidence-based decisions.
The research partners are seeking a means of providing better insights into how a drug interacts with the body, improving the efficiency and productivity of drug discovery.
The project will use novel deep learning methods to create a next generation platform that will better predict the absorption, distribution, metabolism, excretion and toxicity (ADMET) of new drug candidates.
Building on Optibrium’s existing software offering (StarDrop™) and an Intellegens’ deep learning toolkit (Alchemite™), the project will develop and apply novel AI methods across ADMET.
By developing DeepADMET technology the aim is to improve the scope and reliability of drug design parameters, currently inaccessible or unavailable, for the first time.
Matthew Segall, CEO of Optibrium, says: “We will apply cutting edge deep learning methods and new data to address important challenges in drug optimisation.
“The funding from Innovate UK is important validation of our project team’s expertise and the impact it will have on the industry’s efficiency and productivity. We look forward to making these models available to researchers through the StarDrop platform.”
Intellegens’ CEO Ben Pellegrini, added: “Intellegens is extremely excited to be part of this collaboration and looks forward to applying our novel deep learning techniques to help build a next generation platform to improve the drug discovery process.”
Currently, high failure rates mean that nine out of 10 potential drugs fail somewhere between phase 1 trials and regulatory approval, greatly adding to the costs of creating new medicines.
The growth in computer-processing power, availability of large data sets, development of advanced algorithms and major improvements in machine learning presents a great opportunity for drug discovery.
The technology and models created as a result of this project will help guide the selection and design of compounds early in the discovery process, to more quickly identify candidate drugs with a higher chance of success and lower development risk.